Genes (73)
Species: human : 73 | |
Human | SFTPA1 | 653509 | surfactant protein A1 | In pleural effusions due to malignant mesothelioma, very low concentrations of SP-A and CEA can be expected. SP-A and CEA concentrations were measured in pleural effusions from 78 patients with lung adenocarcinoma and 10 with malignant mesothelioma. | Human | NEWENTRY | 192343 | Record to support submission of GeneRIFs for a gene not in Gene (human; man). | Cytokeratin markers (CK5/6 and K903) are useful in differentiating squamous cell carcinoma from adenocarcinoma when malignant mesothelioma is already excluded [cytokeratin 6] | Human | MAGED4B | 81557 | melanoma antigen family D, 4B | At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. | Human | CHEK2 | 11200 | checkpoint kinase 2 | According to our knowledge, this is the first mutation screening of Chk1, Chk2, Apaf1 and Rb1 in human malignant mesothelioma. | Human | MSLN | 10232 | mesothelin | Click here to display 9 evidence detail records. | Human | EBAG9 | 9166 | estrogen receptor binding site associated, antigen, 9 | RCAS1 expression is informative for the follow-up of malignant mesothelioma patients. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma. RCAS1 expression is informative for the follow-up of malignant mesothelioma patients and sRCAS1 in pleural fluid may be useful for the diagnosis of malignant mesothelioma Interestingly, survival of the malignant mesothelioma patients with RCAS1 expression was significantly increased compared with those without (median survival time: 13.0 vs. 4.3 months, p=0.011). We found that 34 out of 38 (89.5%) malignant mesothelioma cells stained for RCAS1. | Human | BCL10 | 8915 | B-cell CLL/lymphoma 10 | The BCL10 gene, located at 1p22, has been implicated in a number of human malignancies, including malignant mesotheliomas (MMs) and colorectal carcinomas. According to the LOH study at intragenic polymorphic sites, deletion of Bcl10 in informative cases was detected in 50% of malignant mesotheliomas, 33% of gastric carcinomas, 23% of breast carcinomas, 20% of hepatocellular carcinomas, 17% of lymphomas, 15% of colorectal carcinomas, 13% of laryngeal carcinomas, and 10% of male germ cell tumors (GCTs). Absence of BCL10 mutations in human malignant mesothelioma. Absence of post-transcriptional RNA modifications of BCL10 in human malignant mesothelioma and colorectal cancer. | Human | CFLAR | 8837 | CASP8 and FADD-like apoptosis regulator | Malignant mesothelioma cells develop an intrinsic resistance to apoptosis induced by death receptors upregulating the expression of the antiapoptotic protein c-FLIP | Human | TNFRSF10A | 8797 | tumor necrosis factor receptor superfamily, member 10a | Malignant mesothelioma cells develop anintrinsic resistance to apoptosis induced by death receptor-4 upregulating the expression of the antiapoptotic protein c-FLIP | Human | TNFRSF10B | 8795 | tumor necrosis factor receptor superfamily, member 10b | We used cell lines derived from a highly chemoresistant tumor, malignant mesothelioma, to learn whether TRAIL was effective alone or together with chemotherapy and whether cooperativity depended on increases in DR5 expression. | Human | TNFRSF10D | 8793 | tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain | Aberrant methylation of DcR1 or DcR2 was present in 70% of primary breast cancers, 31% of primary lung cancers, in 63% of primary malignant mesothelioma (MM), in 60% of prostate cancer, in 42% of bladder cancer, in 100% of cervical cancer, in 43% of ovarian cancer, in 41% of lymphoma, in 26% of leukemia and in 56% of multiple myeloma. | Human | TP63 | 8626 | tumor protein p63 | In pleural malignant effusion, malignant mesothelioma can be identified with positive staining for WT-1 and negative staining for p63 All malignant mesotheliomas were negative for p63. Accordingly, in the present study we examined the expression of calretinin, mesothelin, cytokeratin (CK) 5/6, thrombomodulin, HBME-1, Wilms; tumor-1 (WT-1), Ber-EP4, MOC-31, BG-8, B72.3, carcinoembryonic antigen (CEA), CD15, thyroid transcription factor-1 (TTF-1), p63, and CD5 in 22 thymic carcinomas and 35 thymomas, and compared the results with those of malignant mesothelioma and pulmonary adenocarcinoma. | Human | CDC14A | 8556 | cell division cycle 14A | By radiation hybrid mapping, we localized CDC14A to chromosome band 1p21, a region that has been shown to exhibit loss of heterozygosity in highly differentiated breast carcinoma and malignant mesothelioma. | Human | FOSL1 | 8061 | FOS-like antigen 1 | These studies suggest that inhibition of fra-1 signaling pathways may be a strategy for therapy of malignant mesothelioma. | Human | VEGFC | 7424 | vascular endothelial growth factor C | Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops | Human | VCAM1 | 7412 | vascular cell adhesion molecule 1 | These findings are consistent with the possibility that TNF alpha, IL-13, or other activating signals are released in the tumour micro-environment and regulate the expression of VCAM-1 in malignant mesothelioma cells. Expression of ICAM-1 and VCAM-1 was investigated in tissue sections of 16 cases of malignant mesothelioma (seven epithelial, eight biphasic, and one sarcomatoid) using immunohistochemistry. Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. | Human | TXN | 7295 | thioredoxin | Although the Trx system may have an important role in the drug resistance of malignant mesothelioma, these studies also suggest that multiple factors contribute to the promotion, cell proliferation and apoptosis of malignant mesothelioma cells in vivo. | Human | NKX2-1 | 7080 | | Accordingly, in the present study we examined the expression of calretinin, mesothelin, cytokeratin (CK) 5/6, thrombomodulin, HBME-1, Wilms tumor-1 (WT-1), Ber-EP4, MOC-31, BG-8, B72.3, carcinoembryonic antigen (CEA), CD15, thyroid transcription factor-1 (TTF-1), p63, and CD5 in 22 thymic carcinomas and 35 thymomas, and compared the results with those of malignant mesothelioma and pulmonary adenocarcinoma. This study investigates the immunohistochemical expression of TTF-1 in pleural malignant mesotheliomas (MM) and adenocarcinomas (AC) of the lung, respectively. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Immunoreactivity for pro-SP-B and TTF-1 was examined in paraffin sections of 370 primary lung carcinomas (208 adenocarcinomas, 101 squamous cell carcinomas, and 61 large cell carcinomas) and 95 malignant mesotheliomas, using a pro-SP-B antiserum and a monoclonal TTF-1 antibody with a biotin-streptavidin detection system. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. The expression of pro-SP-B and TTF-1 in adenocarcinomas of the lung but not in malignant mesotheliomas shows that pro-SP-B and TTF-1 staining is useful in differentiating these neoplasms. Where TTF-1 is negative and E-cadherin is positive, a secondary panel of antibodies, including BerEP4 and LeuM1 (CD15) and antibodies directed against CEA, calretinin, cytokeratin 5/6, thrombomodulin, and N-cadherin, is required for differentiation between malignant mesothelioma and pulmonary adenocarcinoma. | Human | TGFB2 | 7042 | transforming growth factor, beta 2 | The effects and the mechanisms of action of transforming (TGF-beta 2) and basic fibroblast (bFGF) growth factors on the synthesis of hyaluronan and proteoglycans (PGs) in human malignant mesothelioma cells have been studied. By contrast, there was differential spatial immunostaining for the TGF-beta isoforms in malignant mesothelioma, with TGF-beta 1 in the stroma but TGF-beta 2 in the tumor cells. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. | Human | TFRC | 7037 | transferrin receptor (p90, CD71) | To evaluate this therapeutic strategy, a monoclonal antibody reactive with human transferrin receptor (7D3) was evaluated for localization in a human malignant mesothelioma transplanted i.p. in athymic nude mice. Immunotoxins directed against human transferrin receptor have been evaluated in a nude mouse model of human malignant mesothelioma. | Human | TFF1 | 7031 | trefoil factor 1 | Staining of malignant mesothelioma for the trefoil protein pS2. | Human | TCF3 | 6929 | transcription factor 3 | In this study, we evaluated the utility of pro-SP-B and ITF-1 in distinguishing pulmonary adenocarcinomas and malignant mesotheliomas. | Human | STAT3 | 6774 | signal transducer and activator of transcription 3 (acute-phase response factor) | strong expression of cytoplasmic inactive STAT3 in NSCLC and malignant mesothelioma cases implies a major role for STAT3 in tumor motility, invasion, and metastasis via a nontranscriptional pathway | Human | ST14 | 6768 | suppression of tumorigenicity 14 (colon carcinoma) | Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. | Human | SSX2 | 6757 | synovial sarcoma, X breakpoint 2 | At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. |
|